Ado-Trastuzumab Emtansine
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 984 publications
Trastuzumab Emtansine-Associated Porto-Sinusoidal Vascular Disorder: Clinical Features and Outcomes from Published Cases.
Journal: Journal of clinical medicine
Published: April 28, 2026
A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 24, 2026
Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support.
Journal: Frontiers in oncology
Published: April 18, 2026
Adverse Event Profiling and Comparative Analysis of HER2-targeting Antibody-drug Conjugates Using Pharmacovigilance Databases.
Journal: In vivo (Athens, Greece)
Published: April 06, 2026
Incidence of Clinically Significant Neutropenia and Complications Related to Antibody-Drug Conjugates: A Real-World Study at the University of California.
Journal: Cancers
Published: April 01, 2026
The Changing Landscape of Breast Cancer Treatment.
Journal: Chirurgia (Bucharest, Romania : 1990)
Published: April 01, 2026
Next-generation antibody-drug conjugates in drug-resistant solid tumors: promise, toxicity, and the emerging challenge of acquired resistance.
Journal: Annals of medicine and surgery (2012)
Published: March 24, 2026
Antibody-drug conjugate sequencing in HER2-positive metastatic breast cancer: Real-world outcomes of trastuzumab deruxtecan with and without prior T-DM1 exposure.
Journal: Breast (Edinburgh, Scotland)
Published: January 21, 2026
Last Updated: 09/26/2026